Desmoglein 3-ELISA

Lenz, Petra H.; Amagai, Masayuki; Volc‐Platzer, Beatrix; Stingl, Georg; Kirnbauer, Reinhard

doi:10.1001/archderm.135.2.143

Cited by 73 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cloning of the Dsg3 gene and expression of the protein in a native conformation has enabled the recent development of a specific and sensitive ELISA for the detection of PV antigen (11). ELISA scores have been reported to be sensitive and also more specific than the IIF test and to correlate well with clinical disease activity (11).…”

Section: Discussionmentioning

confidence: 99%

A Case of Pemphigus Vulgaris Successfully Treated with Single Filtration Plasmapheresis: A Correlation of Clinical Disease Activity with Serum Antibody Levels

Yano

Ishiji

Kamide

et al. 2000

The Journal of Dermatology

View full text Add to dashboard Cite

We report a patient with pemphigus vulgaris (PV) successfully treated with single filtration plasmapheresis. A 40-year-old man with PV was started on therapy with prednisolone (PSL). Although the dosage of PSL was doubled, and both cyclosporin A (CyA) and pulse therapy were added, the disease was not controlled. After single filtration plasmapheresis began, most of the eroded lesions on the trunk reepithelialized. A switch to double filtration was followed by recurrence. Finally, additional treatments with single filtration plasmapheresis were required to obtain remission. To evaluate the efficacy of the treatment, circulating antibodies were measured by immunofluorescence (IIF) and enzyme-linked immunosorbent assays (ELISAs) using recombinant desmoglein (Dsg) 3. IIF titer and the ELISA scores correlated with the clinical disease activity. It is suggested that ELISA was more sensitive than IIF.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Pemphigus Vulgaris Successfully Treated with Single Filtration Plasmapheresis: A Correlation of Clinical Disease Activity with Serum Antibody Levels

Yano

Ishiji

Kamide

et al. 2000

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…The recent availability of cDNA clones for pemphigus antigens has allowed the production of recombinant DSG1 and DSG3 molecules and the development of an enzyme-linked immunosorbent assay (ELISA) approach in order to determine levels of antibodies to them [4, 5]. This assay has shown a high sensitivity and specificity with respect to the possibility to diagnose pemphigus and to differentiate PV from PF.…”

Section: Introductionmentioning

confidence: 99%

Detection of Autoantibodies against Recombinant Desmoglein 1 and 3 Molecules in Patients with Pemphigus vulgaris: Correlation with Disease Extent at the Time of Diagnosis and during Follow-Up

Fortina

Faggion

Pigozzi

et al. 2009

Clinical and Developmental Immunology

View full text Add to dashboard Cite

The recent availability of cDNA clones for pemphigus antigens has allowed the production of recombinant desmoglein 1 and desmoglein 3 molecules and the development of an ELISA approach in order to determine levels of antibodies to them. The aim of the study was to determine the relationship between autoantibodies levels and the extent of both mucosal and skin lesions in 20 patients with pemphigus vulgaris at the time of diagnosis and during follow-up. For the detection of autoantibodies by ELISA we used the recombinant proteins expressing overlapping sequences with the entire extracellular desmoglein 1 and desmoglein 3 domains. We showed that in presence of mucosal lesions there was a correlation between extension of mucosal involvement and autoantiboidies titres against both desmoglein 1 and desmoglein 3, whereas in presence of skin lesions there was a statistically significant correlation between extension of skin lesions and autoantibodies titres against desmoglein 3, but not against desmoglein 1. A not negligible number of patients showed variations of the desmoglein 3 autoantibodies titre which did not correlate with the severity of both cutaneous and mucosal involvement. Similar results were obtained analyzing autoantibodies titres against desmoglein 1. In conclusion, we believe that the utilization of recombinant desmoglein 1 and desmoglein 3 proteins by ELISA should be used with caution to monitor disease severity and response to therapy, although it remains a high specific test for the initial diagnosis of pemphigus and the identification of a change in the clinical phenotype of this condition.

show abstract

“…Desmoglein ELISA[1922] is a sensitive and specific test to detect auto-antibody against desmoglein (DsG) proteins, both DsG-1 and DsG-3. Quantitative data from ELISA on DsG-1 and DsG-3 show a relationship between DsG-1 antibody and skin severity and between DsG-3 antibody level and oral disease severity.…”

mentioning

confidence: 99%